DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Jefferies Initiates Coverage On Beam Therapeutics with Buy Rating, Announces $32 Price Target

Jefferies analyst Michael Yee initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and a $32 price target.

Benzinga · 03/02/2020 11:27

Jefferies analyst Michael Yee initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and a $32 price target.